A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

Andrea Bertotti(University of Turin), Livio Trusolino(University of Turin)

Cancer Discovery

September 3, 2011

10.1158/2159-8290.cd-11-0109

Cited by 948

Related Papers

Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

|Nature|2019|1.4k

MET signalling: principles and functions in development, organ regeneration and cancer

|Nature Reviews Molecular Cell Biology|2010|1.2k

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

|The Lancet Oncology|2016|1k

The genomic landscape of response to EGFR blockade in colorectal cancer

|Nature|2015|495

Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

|Nature Communications|2017|322